Washington: Monoclonal antibodies are in high demand for Covid treatment in the United States, especially among those who reject the infectious disease vaccine, prompting the Joe Biden administration to place new limits on drug orders, according to the media.

Overall, demand for treatment with monoclonal antibodies, lab-made antibodies given to a person that help their immune system prevent the spread of infection, has increased 20-fold since mid-July, CBS reported. News.

Alabama, Florida, Texas, Mississippi, Tennessee, Georgia and Louisiana have accounted for 70% of monoclonal antibody orders in recent weeks, according to the spokesperson for the Department of Health and Human Services ( HHS).

Of those states, only Florida has fully vaccinated more than half of its total population, according to the Centers for Disease Control and Prevention.

The rest rank in the bottom 10 states for immunizations nationwide.

All seven rank among the top half of states with the highest rates of daily hospitalizations for Covid-19 in recent weeks, according to the report.

“Given this reality, we must work to ensure that our supply of these life-saving therapies remains available to all states and territories, not just some,” the spokesperson said.

President Biden announced last week that his administration was increasing the pace of free weekly deliveries of monoclonal antibodies by 50% for the month of September, CNET reported.

The administration is also launching “monoclonal antibody strike teams” to help healthcare workers and hospital staff administering the treatment.

The HHS department will change the rules that allow more providers, including pharmacists, to administer the treatment, according to the report.

It will also allocate the drugs to state health departments, “based on the burden of Covid-19 cases” and the demand for treatment with Regeneron’s REGEN-COV and Eli Lilly’s bamlanavimab and etesevimab combination.

According to some preliminary research, the treatment – Regeneron’s REGEN-COV and Eli Lilly’s bamlanavimab and etesevimab combination – reduces the risk of hospitalization or death by about 70%.

Earlier in August, Anthony Fauci, the president’s chief medical adviser, said monoclonal antibodies are “underused” and the drug can reduce the risk of hospitalization or death from Covid by 70-85%. 19.

However, drugs should not be used as a “substitute for vaccination”. but there has been a lack of awareness and access to monoclonal antibody therapy.

The therapy is also available in India and hospitals including Medanta in Gurugram, BLK-Max Super Specialty and Sir Gangaram in New Delhi have successfully implemented the treatment.

About The Author

Related Posts

Leave a Reply

Your email address will not be published.